NM_014176.4(UBE2T):c.179+5G>A

Base Editing (ABE8e) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Fanconi anemia, complementation group T (FANCT / UBE2T-related Fanconi anemia) targeting the UBE2T c.179+5G>A variant (Pathogenic, intron variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Correct UBE2T loss-of-function variants in autologous hematopoietic stem cells at chr1:202332745 region (or other pathogenic UBE2T loci) to restore FANCD2/FANCI monoubiquitination and prevent bone mar. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: UBE2T NM_014176.4(UBE2T):c.179+5G>A is classified as Pathogenic (ClinVar variation ID 199437). Molecular consequence: intron variant. 2. Epidemiology: Fanconi anemia (all subtypes) is an ultra-rare inherited bone marrow failure and cancer predisposition syndrome with an estimated incidence of roughly 1–5 per 1,000,000 individuals. Registry and review data indicate that the cumulative incidence of bone marrow failure exceeds 50% by age 40 years, wi 3. Standard of care: Current management for Fanconi anemia, including FANCT, is based on supportive care plus hematopoietic stem cell transplantation (HSCT). Supportive measures include androgen therapy (e.g., oxymetholone, danazol) that can transiently improve blood counts in about half of patients, granulocyte colony- 4. Pipeline: Gene therapy for Fanconi anemia is in active clinical development, primarily for FANCA. Early-phase ex vivo lentiviral FANCA gene addition trials (Phase I/II) have shown sustained engraftment of corrected hematopoietic stem cells and improved hematopoiesis without myeloablative conditioning and with 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting UBE2T c.179+5G>A with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.